HC Wainwright Cuts Alumis (NASDAQ:ALMS) Price Target to $14.00

Alumis (NASDAQ:ALMS) had its target price lowered by HC Wainwright from $15.00 to $14.00 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Alumis’ Q1 2025 earnings at ($1.03) EPS, Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.74) EPS and FY2025 earnings at ($3.22) EPS.

A number of other equities research analysts have also recently commented on ALMS. Oppenheimer started coverage on shares of Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $25.86.

Alumis Stock Down 8.5 %

Shares of ALMS stock opened at $4.31 on Tuesday. Alumis has a 52-week low of $3.18 and a 52-week high of $13.53. The company has a 50-day simple moving average of $5.52 and a two-hundred day simple moving average of $7.72.

Insider Buying and Selling at Alumis

In other news, Director Alan Colowick bought 16,104 shares of the company’s stock in a transaction dated Tuesday, April 1st. The stock was bought at an average cost of $6.97 per share, for a total transaction of $112,244.88. Following the completion of the acquisition, the director now owns 16,104 shares in the company, valued at approximately $112,244.88. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Martin Babler purchased 15,650 shares of Alumis stock in a transaction that occurred on Tuesday, April 1st. The shares were acquired at an average price of $6.44 per share, for a total transaction of $100,786.00. Following the acquisition, the chief executive officer now owns 106,454 shares in the company, valued at $685,563.76. This trade represents a 17.23 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Institutional Trading of Alumis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Foresite Capital Management V LLC raised its holdings in Alumis by 3.5% in the 4th quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock worth $45,426,000 after purchasing an additional 194,459 shares in the last quarter. Foresite Capital Management VI LLC purchased a new stake in Alumis in the fourth quarter worth about $33,033,000. Tang Capital Management LLC lifted its holdings in Alumis by 40.6% in the fourth quarter. Tang Capital Management LLC now owns 600,000 shares of the company’s stock worth $4,716,000 after buying an additional 173,406 shares during the period. Ally Bridge Group NY LLC boosted its position in Alumis by 6.4% during the 4th quarter. Ally Bridge Group NY LLC now owns 445,259 shares of the company’s stock valued at $3,500,000 after acquiring an additional 26,843 shares in the last quarter. Finally, Towerview LLC grew its holdings in shares of Alumis by 9.2% during the 4th quarter. Towerview LLC now owns 415,000 shares of the company’s stock worth $3,262,000 after acquiring an additional 35,000 shares during the period.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.